• Home
  •  / Vertex Pharmaceuticals

Vertex Pharmaceuticals

OverviewSuggest Edit

Vertex Pharmaceuticals is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases and cancer.
TypePublic
Founded1989
HQBoston, MA, USMap
Websitevrtx.com
Employee Ratings3.6More
Overall CultureA+More
View Jobs (339)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2020)3,400(+14%)
Job Openings339
Revenue (FY, 2020)$6.2 B(+50%)
Share Price (Jul 2021)$202.2
Cybersecurity ratingCMore

Key People/Management at Vertex Pharmaceuticals

Jeffrey Leiden

Jeffrey Leiden

Executive Chairman
Reshma Kewalramani

Reshma Kewalramani

Chief Executive Officer, President & Director
Sangeeta N. Bhatia

Sangeeta N. Bhatia

Director
David Altshuler

David Altshuler

Executive Vice President, Global Research and Chief Scientific Officer
Carmen Bozic

Carmen Bozic

Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Stuart A. Arbuckle

Stuart A. Arbuckle

Executive Vice President and Chief Commercial and Operations Officer
Show more

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has offices in Boston, San Diego, Washington, Watertown and in 18 other locations
Boston, MA, US (HQ)
50 Northern Ave
San Diego, CA, US
3215 Merryfield Row
Washington, DC, US
1050 K St NW
Watertown, MA, US
490 Arsenal Way #110
St Leonards, AU
level 3 suite 3/601 Pacific Hwy
Wien, AT
Lehrbachgasse 13
Show all (27)

Vertex Pharmaceuticals Financials and Metrics

Vertex Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Vertex Pharmaceuticals's revenue was reported to be $6.21 b in FY, 2020 which is a 49.1% increase from the previous period.
USD

Revenue (Q1, 2021)

1.7b

Gross profit (Q1, 2021)

1.5b

Gross profit margin (Q1, 2021), %

88.8%

Net income (Q1, 2021)

653.1m

EBIT (Q1, 2021)

887.8m

Market capitalization (28-Jul-2021)

52.4b

Closing stock price (28-Jul-2021)

202.2

Cash (31-Mar-2021)

6.3b

EV

46.9b
Vertex Pharmaceuticals's current market capitalization is $52.4 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

3.0b4.2b6.2b

Revenue growth, %

37%49%

Cost of goods sold

409.5m547.8m736.3m

Gross profit

2.6b3.6b5.5b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

858.4m941.3m949.8m1.5b1.5b1.5b1.7b

Cost of goods sold

95.1m135.7m131.9m162.5m184.5m186.2m192.3m

Gross profit

763.3m805.6m817.9m1.4b1.3b1.4b1.5b

Gross profit Margin, %

89%86%86%89%88%88%89%
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

2.7b3.1b6.0b

Accounts Receivable

409.7m633.5m885.4m

Prepaid Expenses

140.8m213.5m308.4m

Inventories

124.4m167.5m280.8m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

2.9b3.3b3.4b3.6b4.8b5.4b6.3b

Accounts Receivable

438.3m464.9m443.3m845.3m791.8m791.9m977.6m

Prepaid Expenses

130.0m151.8m175.1m223.6m232.6m270.0m338.9m

Inventories

136.7m143.0m162.3m187.1m219.2m245.5m298.9m
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

2.1b1.2b2.7b

Depreciation and Amortization

72.4m106.9m109.5m

Inventories

(32.0m)(64.0m)(132.0m)

Accounts Payable

36.6m(22.8m)51.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

268.6m536.1m593.6m602.8m1.4b2.1b653.1m

Depreciation and Amortization

27.1m54.8m80.7m26.8m53.5m80.2m28.8m

Inventories

(13.1m)(25.2m)(45.3m)(27.4m)(64.4m)(94.9m)(22.8m)

Accounts Payable

(24.1m)(28.1m)(12.2m)14.3m14.7m16.2m(10.6m)
show all
USDFY, 2018

EV/EBIT

63.4 x

EV/CFO

31.7 x

Revenue/Employee

1.2m

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.4 x

P/E Ratio

20.5
Show all financial metrics

Vertex Pharmaceuticals Operating Metrics

FY, 2018FY, 2019FY, 2020

Products

456
Show all operating metrics

Vertex Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Semma TherapeuticsSeptember 03, 2019$950 m
Exonics TherapeuticsJune 06, 2019$245 m
Aurora Biosciences CorporationApril 30, 2001
The Vertex Foundation, Inc.
Torreyana Insurance Company, Inc.
Vertex Farmaceutica do Brasil LTDA
Vertex Holdings, Inc.
Vertex Pharmaceuticals (Australia) Pty. Ltd.
Vertex Pharmaceuticals (Canada) Incorporated
Vertex Pharmaceuticals (Cayman 509) Limited
Show more

Vertex Pharmaceuticals Revenue Breakdown

Embed Graph

Vertex Pharmaceuticals revenue breakdown by business segment: 62.3% from TRIKAFTA/KAFTRIO , 10.1% from SYMDEKO/SYMKEVI, 14.6% from ORKAMBI and 12.9% from KALYDECO

Human Capital Metrics

Source: www.vrtx.com
Embed Graph
Show all human capital metrics

Vertex Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

Learn more about our premium products
SecurityScorecard logo

Vertex Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Vertex Pharmaceuticals Online and Social Media Presence

Vertex Pharmaceuticals's Trends

Embed Graph

Vertex Pharmaceuticals Company Culture

  • Overall Culture

    A+

    92/100

  • CEO Rating

    A+

    86/100

  • Compensation

    A+

    96/100

  • Diversity

    A+

    91/100

Learn more on Comparably

Vertex Pharmaceuticals Blogs

July 29, 2021

Vertex Reports Second-Quarter 2021 Financial Results

- Product revenues of $1.79 billion , an 18% increase compared to Q2 2020 - - Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B -   - Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021; multiple additional clinical milestones
July 28, 2021

Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis

- Phase 2 study met primary endpoint and all secondary endpoints - - Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) - - Initiation of
July 19, 2021

Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

- Proof-of-concept study of VX-548 in acute pain following bunionectomy surgery open for enrollment - - Second Phase 2 study of VX-548 in acute pain following abdominoplasty surgery to begin in the coming weeks - BOSTON --(BUSINESS WIRE)--Jul. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq:
July 16, 2021

Vertex to Announce Second-Quarter 2021 Financial Results on July 29

Vertex to Announce Second-Quarter 2021 Financial Results on July 29 Content Import Fri, 07/16/2021 - 16:01 Vertex to Announce Second-Quarter 2021 Financial Results on July 29 Jul 16, 2021 This release is a backfill from a News Wire Webcast…
June 28, 2021

Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients

Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients Content Import Mon, 06/28/2021 - 09:27 Vertex Announces National Reimbursement Agreement in France for KAFTR…
June 25, 2021

Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis

- Reimbursement agreement also includes certain future indication extensions across all Vertex CF medicines - - Approximately 1,400 patients will now have access to a CFTR modulator for the first time - LONDON --(BUSINESS WIRE)--Jun. 25, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
Show more

 Vertex Pharmaceuticals Frequently Asked Questions

  • When was Vertex Pharmaceuticals founded?

    Vertex Pharmaceuticals was founded in 1989.

  • Who are Vertex Pharmaceuticals key executives?

    Vertex Pharmaceuticals's key executives are Jeffrey Leiden, Reshma Kewalramani and Sangeeta N. Bhatia.

  • How many employees does Vertex Pharmaceuticals have?

    Vertex Pharmaceuticals has 3,400 employees.

  • What is Vertex Pharmaceuticals revenue?

    Latest Vertex Pharmaceuticals annual revenue is $6.2 b.

  • What is Vertex Pharmaceuticals revenue per employee?

    Latest Vertex Pharmaceuticals revenue per employee is $1.8 m.

  • Who are Vertex Pharmaceuticals competitors?

    Competitors of Vertex Pharmaceuticals include Amphastar Pharmaceuticals, Maruishi Pharmaceutical and Olon.

  • Where is Vertex Pharmaceuticals headquarters?

    Vertex Pharmaceuticals headquarters is located at 50 Northern Ave, Boston.

  • Where are Vertex Pharmaceuticals offices?

    Vertex Pharmaceuticals has offices in Boston, San Diego, Washington, Watertown and in 18 other locations.

  • How many offices does Vertex Pharmaceuticals have?

    Vertex Pharmaceuticals has 27 offices.